Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $3,854,281.48 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 85,918 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. The trade was a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock traded up $0.94 during trading hours on Thursday, reaching $44.94. The company had a trading volume of 697,997 shares, compared to its average volume of 369,839. Sionna Therapeutics, Inc. has a one year low of $16.38 and a one year high of $48.44. The business has a fifty day simple moving average of $40.18 and a 200 day simple moving average of $39.52. The firm has a market cap of $2.03 billion, a PE ratio of -23.28 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). On average, research analysts forecast that Sionna Therapeutics, Inc. will post -2.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SION shares. Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. JonesTrading boosted their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. BTIG Research reaffirmed a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Finally, Stifel Nicolaus raised their price target on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $53.22.

Institutional Investors Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SION. Goldman Sachs Group Inc. purchased a new position in Sionna Therapeutics in the 1st quarter worth approximately $667,000. Woodline Partners LP purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at $837,000. Geode Capital Management LLC lifted its holdings in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after acquiring an additional 153,712 shares during the last quarter. Rhumbline Advisers purchased a new position in Sionna Therapeutics in the second quarter worth $307,000. Finally, New York State Common Retirement Fund bought a new position in Sionna Therapeutics in the second quarter valued at $118,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.